Breast Cancer

The imaging agent and visualization system will be an adjunct to standard of care to reduce residual cancer in the lumpectomy cavity during initial surgery.

US Preventive Services Task Force also called for more research into how to address screening and treatment disparities faced by racial and ethnic minorities.

Alpelisib plus the antioxidant N-acetylcysteine sensitizes NF1 knockout cells to PI3Kα inhibition and reverts their glycolytic phenotype in patients with advanced forms of breast cancer.

Study examines association between breast cancer survival and neighborhood-level measures such as socioeconomic status.

The system is considered effective at identifying residual breast cancer following surgical resection.

Infusion reactions in the switching group did not occur with switching, but rather only with reference trastuzumab administration.

Study results show significant differences in pCR rates, but the differences were not subtype-specific.

Oncology pharmacist discusses recent clinical trial data and what it could mean for patient outcomes.

Certain populations have been found to have differing prognoses, such as African American patients, who have an earlier onset of disease with a higher likelihood of an aggressive tumor type and shorter survival.

The implementation of genetic testing for patients prescribed medications associated with progressive multifocal leukoencephalopathy is likely to improve safety outcomes.

Ribociclib plus endocrine therapy demonstrates a reduction in the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

Drugs such as pembrolizumab, sacituzumab govitecan, and datopotamab deruxtecan all have growing bodies of evidence illustrating which patients with cancer are most likely to benefit and in which settings.

3D biofabrication models reflect increasing global awareness of the ethics of preclinical studies and an increased need for determining therapeutic efficacy differences.

Therapy effectively treats cells harboring HR deficiencies, including those of specific types of ovarian, breast cancers.

Most patients used nonproprietary drugs, which may contribute to the reduction of out-of-pocket costs for the treatment of invasive breast cancer.

Trastuzumab deruxtecan was approved by the FDA for HER2-low breast cancer treatment in 2022 and could also benefit some patients with hormone receptor-positive or triple-negative disease.

The vaccine targets a protein that is no longer found after lactation in normal aging tissues but is present in most triple-negative breast cancers.

Indication for abemaciclib (Verzenio; Eli Lilly and Company) in combination with endocrine therapy expanded for the adjuvant treatment of adults with hormone receptor–positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer with a high risk of recurrence.

The approach was based on previous research suggesting that foods rich in carotenoids, lycopene, certain B vitamins, and omega 3 fatty acids improved fatigue in survivors of breast cancer.

Metformin may accelerate paclitaxel’s actions on cell replication in endometrial cancer.

Incidence of regional tumor recurrence in patients with HR–positive breast cancer did not significantly differ between patients who received post operational radiotherapy.

HER2-low disease demands a different approach from that of HER2-negative disease.

Numerous clinical trials are investigating the next generation of PARPi.

Cancer screening rates were still below the expected rates of return in both 2021 and 2022.

Patients with triple-negative breast cancer treated with veliparib had statistically significantly longer survival than those given placebo.

Ultra-processed food consumption linked to an increased risk of developing and dying from ovarian cancer and breast cancer.

Sacituzumab govitecan-hziy (Trodelvy) is a conjugated Trop-2-directed antibody and topoisomerase inhibitor previously approved for patients with triple-negative breast cancer.

The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.

Findings suggest cancer may have overtaken cardiovascular disease as a leading cause of death in individuals with type 2 diabetes.

CAR T cell gel eliminated the residual tumor cells in almost all mouse models, allowing the mice to survive when they otherwise would have succumbed to tumor recurrence.